|Location:||Kingston upon Hull|
|Funding for:||UK Students, EU Students, International Students|
|Funding amount:||£17,668 per annum. This rises each year in line with the UKRI's recommended stipend allowance.|
|Hours:||Full Time, Part Time|
|Placed On:||16th January 2023|
|Closes:||10th February 2023|
About this project
Applications are invited for an exciting 3-year fully funded PhD studentship to commence in September 2023.
This PhD project strives to develop a new approach for the modular design and assembly of theragnostic radiopharmaceuticals. The clinical value of theragnostics for the diagnosis and treatment of disease has been evidenced by prominent phase 3 clinical trials. It is recognised that desirable pharmacokinetic properties, which result in increased target uptake and retention, but reduce non-target accumulation, are vital to ensure maximum therapeutic efficacy and minimise side-effects. In this project, a new platform technology to facilitate convenient modular assembly of theragnostic radiopharmaceuticals will be developed and evaluated in vitro and in vivo. This approach will enable the rapid development of large libraries of radioconjugates, and accelerate the development of novel theragnostic agents for clinical translation.
For informal inquiries, please contact Dr Louis Allott (firstname.lastname@example.org)
About the research cluster / about the research environment
Theragnostics is a rapidly developing area of nuclear medicine which combines diagnosis and therapy into a single unified strategy for the treatment of disease. We are already implementing approved theragnostics into the clinic at Castle Hill Hospital, for the benefit of cancer patients in the surrounding area. Complementary to this is our ambition to expand our own research capacity around novel theragnostic radiopharmaceuticals and their application to disease. In 2022, we established the Hull University Theragnostics (HUT) PhD cluster. The cluster unites two successful research groups in molecular imaging and wound research, to collaborate and explore new ground in theragnostic radiopharmaceutical development with applications in cancer and wounds.
Primary supervisor: Dr Louis Allott; 2nd supervisors: Dr Azeem Saleem, Prof Carl Redshaw
Submission of thesis
Submission of your final thesis is expected within three years and three months from the start of your PhD scholarship for full-time and within five years and six months if studying part-time.
Eligibility and entry requirements
We welcome applicants with a 1st or 2:1 undergraduate degree in chemistry, biochemistry, or a related discipline. A master’s degree in these subjects or a more specifically relevant discipline (e.g. molecular imaging or radiopharmaceuticals) would be advantageous.
This opportunity comes with a Home fee waiver only, which will not cover the full International fee. You will therefore need to pay the difference between the Home fee and the International fee and will need to provide evidence that you have sufficient funds to cover this.
How to apply Applications are via the University of Hull webpage
Closing date for applications
10 February 2022
Type / Role: